Using expression data from patient samples and genomic information on TF binding to super-enhancers, starting from a list of 1667 human TFs we calculated a patient-specific activity score and identified 34 with perturbed activity in the cancer samples, as evidenced by the expression of their direct targets. The gene discussed is TF; the disease is cancer.